| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.18 | 0.001 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.002 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.18 | 0.002 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.002 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.17 | 0.004 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |